Psychedelic Law, Science & Policy

A framework is only worth having if it can be shown wrong in a way someone can measure. This paper turns the compound-race-pathology framework (Paper 8b) into five concrete, framework-distinct trial designs that others can run, refine, or disprove, each fixing in advance what would count as failure, across three pathology classes (psychiatric, post-viral, autoimmune) with full trial-design templates. Target venue: Frontiers in Medicine — Translational Medicine (primary); fallback Trials (BMC methodology). Abstract. Compound race pathology (Paper 8b) specifies a framework for multi-scale disease progression that exceeds any single scale's control coefficient. This translational companion paper operationalises the framework into five framework-distinct intervention protocols with full trial-design templates (Bayesian adaptive platform; substrate-vector entry criteria; per-template power calculations; framework-pivotal vs component-test stratification). Protocols span: (§3.1) ketamine + structured CBT consolidation for treatment-resistant depression; (§3.2) psilocybin + substrate-vector-matched integration for TRD; (§3.3) long COVID multi-target factorial; (§3.4) TRD upfront multi-axis substrate-vector profiling with a proposed six-axis biomarker panel (inflammation, HPA, microbiome, cognitive pattern, behavioural activation deficit, sleep substrate; target cost $400–1500; analytical validation specified as a precondition); and (§3.5) CAR-T + tolerance-substrate-stabilisation for autoimmune. Trial-design contributions. Box-format trial-design templates with substrate-vector entry criteria, 4D stratification analysis (substrate-vector × demographic × clinical × outcome), framework-pivotal R-condition specification per protocol, and adaptive-modification trajectory documentation. Proposed reporting items for substrate-stratified compound-mechanism trials (§4.6) cover substrate-vector measurement at intake, stratification-decision rules, intervention-modification trajectory, and 4D-comparison-analysis — offered as items such trials should consider rather than as a standard from a standards body. The calibrated-retrieval prediction (calibration-aware intervention preserves the recognition-commit slope; calibration-naive flattens it), distinct from Paper 8b's R1–R10 set, anchors the calibrated-retrieval-practice mechanism (Paper 1 §5.8.7) as a measurable clinical-substrate axis. Empirical anchors. Wilkinson 2017/2021 ketamine + CBT (Category B durability anchor); Carhart-Harris 2021 NEJM psilocybin-vs-escitalopram (primary p = 0.17 NS — framework re-frames as R10 sub-population-conditional pattern); Müller CASTLE 2026 SLE/IIM/SSc gradient (A1/A2/A3 sub-classification empirical anchor); CBT-ENDURE NCT04760652 (Yale Sanacora-Wilkinson, n = 100, readout 2026–2027); STIMULATE-ICP and RECOVER-AUTONOMIC (long COVID factorial designs); Tsimberidou 2020 IMPACT precision oncology framework. The post-CAR-T relapse mechanism (Grenov 2025) is a bioRxiv preprint, disclosed as such; all other load-bearing citations are peer-reviewed. Framework-distinctness criterion. Each protocol is positioned as framework-distinct from precision-medicine biomarker-stratified single-axis stratification by virtue of the coupling-across-scales prediction operationalised in Paper 8b §4.4: intervention at the most rate-limiting axis produces secondary modification at coupled axes within cross-scale-propagation timescales. The trial-designs incorporate cross-axis longitudinal trajectory measurement to operationalise this prediction at trial scale. Author position and invitation. The author (Pødenphant Lund) is an independent researcher without clinical credentials in the disease-domains the protocols span, without institutional affiliation, and without a clinical consortium — a venue-fit constraint the paper acknowledges explicitly, and the reason it targets a venue hospitable to research-programme papers from independent researchers. The hypothesis-and-invitation fram

Cancer is rarely one button pressed; it is a series of small steps, which is why drug combinations beat single drugs. This paper proposes that this shape, many small steps adding up with no single one in control, is the shared form behind a whole group of conditions. It is a framework-theoretic account of compound disease progression and intervention, applying the Friction Theory architecture (Pødenphant Lund 2026b, Paper 1) to cancer, autoimmune disease, ME/CFS and long COVID, and treatment-resistant depression as instances of compound multi-scale race pathology. Target venue: Cell Reports Medicine (primary); fallbacks PLOS Medicine, Nature Communications. Abstract. Several major chronic and progressive diseases share a clinical signature that single-mechanism explanations have struggled to capture: chronic multi-system dysregulation that responds poorly to single-target therapy, presents with substantial inter-individual heterogeneity, and produces episodic exacerbations or treatment-failure patterns that cannot be reduced to any one pathway. We propose that these conditions are framework-distinct instances of compound race pathology: disease progression produced by coupled multi-scale RACE-architectures where each contributing scale resolves its own race under commit-pressure, hysteretic trace accumulates across scales, and the compound mechanism cannot be addressed by intervention bounded at any single scale's control coefficient. Central formal apparatus. The paper extends Metabolic Control Analysis (Kacser & Burns 1973; Heinrich & Rapoport 1974) — established for steady-state biochemical pathways — to multi-scale disease progression under explicit assumption-set transfer. Heinrich & Rapoport's general distributed-linear-control formulation applies to any system with a conserved scalar under specifiable assumptions; the framework specifies (a) progression-rate as the conserved scalar additive by hysteretic-trace deposition, (b) control coefficients per scale operationalised via factorial design where data permit, (c) linear-response approximation valid in the linear regime, with (d) modified formalism (non-linear interaction terms; cascade percolation per Buldyrev et al. 2010; Hill-equation saturation) for the three non-linear regimes specified in §2.3. Worked-example operationalisation candidates: rheumatoid arthritis (RA, O'Dell triple-DMARD anchor) and heart failure with reduced ejection fraction (HFrEF, included as an applicability-mapping case outside the framework's construction-set in §3.5, with COPD triple-therapy and T2DM combination-therapy registered as the genuinely adversarial forward tests). Hysteresis-fighting taxonomy. Three categories distinguish wholesale attractor-perturbation interventions by durability profile, with sub-classification by substrate-reversibility: A1 cellular reversible (HSCT MS, FMT for recurrent C. difficile, CAR-T SLE drug-free remission); A2 mixed (HSCT SSc, CAR-T IIM); A3 fibrotic halt-only (CAR-T SSc no-progression). Empirically anchored on the CASTLE 2026 SLE/IIM/SSc gradient (Müller et al. 2026, Nature Medicine). Category B (substrate-modification with consolidation requirement): ketamine + CBT (Wilkinson 2017/2021), psilocybin-assisted TRD (Carhart-Harris 2021), HBOT for long COVID. Category C (state-perturbation requiring maintenance): SSRI/SNRI, esketamine, ECT without continuation. Ten empirical predictions plus R1–R10 falsification set with explicit framework-pivotal vs component-test distinction. R3 (substrate-vector predicts response in compound disease) and R5 (CAR-T SLE/IIM/SSc substrate-reversibility gradient at n ≥ 100) are pre-committed as framework-pivotal: their joint disconfirmation refutes the framework's central compound-multi-scale-RACE mechanism; no graceful-degradation clause permits joint survival. R1, R2, R4, R6–R10 are component-tests: their disconfirmation forces revision of specific framework components while the central mechanism is preserved. Substrate

Abstract Rationale Attention-deficit hyperactivity disorder (ADHD) shows substantial heterogeneity in symptoms and cognitive deficits. According to the Triple Pathway Model, this variability may stem from impairments in three neuropsychological domains: inhibition, motivation, and temporal processing. Repeated low-dose administration of psychedelics is being explored as a treatment for ADHD, but evidence from controlled studies in this population remains limited. Objectives This study investigated performance across neuropsychological domains relevant to ADHD: attention, inhibition, motivational processing, and temporal processing, before and after a six-week biweekly low-dose lysergic acid diethylamide (LSD) treatment (20 µg) in adults with ADHD. Based on previous findings, we expected improvements in attention and temporal processing and explored whether baseline ADHD symptoms and domain-specific task performance predicted treatment outcomes. Methods This study presents a secondary analysis of a double-blind, placebo-controlled, parallel group trial. Performance on objective behavioral tasks was assessed at baseline and after six weeks of treatment, before intake of the final dose. Results Fifty-three patients were randomized to LSD ( n = 27) or placebo ( n = 26), and 46 completed the study (LSD: n = 23; placebo: n = 23). An effect of LSD was observed on temporal processing (Time Reproduction Task), leaving performance on other tasks unaffected. Exploratory analyses indicated that baseline performance differentially predicted outcomes related to inhibition and time reproduction in the LSD and placebo groups. Conclusions These findings do not provide convincing evidence for broad cumulative benefits of low-dose LSD treatment across neuropsychological domains in adults with ADHD. The observed effect was limited to a single time reproduction measure and should be interpreted cautiously, particularly given the absence of corresponding improvements in clinical symptoms in the parent trial. Future studies should investigate the robustness of this finding and whether effects are acute, cumulative, or subgroup-specific. Registry ClinicalTrials.gov, TRN: NCT05200936, Registration date: 21 December 2021.

Abstract Ebselen has been shown to induce a positive emotional processing bias and brain neurochemistry in healthy volunteers. However, little is known about its effects on resting-state functional connectivity (rs-FC) in depressed patients who show inadequate responses to standard antidepressants. The study aimed to investigate the effect of ebselen as an add-on treatment on rs-FC in this population. We conducted a randomised, double-blind, placebo-controlled trial involving depressed patients who were not responsive to their current treatment. Participants received either ebselen 600 mg twice daily or placebo for seven days. Resting-state functional magnetic resonance imaging was conducted at baseline and on day seven. Resting-state data were analysed using seed-based analysis and independent component analysis. Greater changes in rs-FC between the pregenual anterior cingulate cortex and the cerebellum were observed in ebselen than in placebo, but became negligible after corrections for multiple comparisons. We identified treatment effects within visual networks and between visual and sensorimotor networks, however, these did not survive correction for multiple comparisons. Short-term ebselen treatment in depressed patients with inadequate antidepressant responses did not produce significant changes in rs-FC. These findings may reflect limitations related to the short treatment duration and small and heterogeneous sample.

Research objective: The aim of this study was to present the current state of knowledge about bipolar affective disorder (BD) — its classification, clinical picture, pharmacological treatment and alternative methods, with particular emphasis on bipolar depression. Methodology: The study is based on a narrative review of recent scientific literature concerning bipolar affective disorder, conducted using the PubMed database with the following keywords: bipolar disorder; bipolar depression; lithium; atypical neuroleptics; ketamine; psilocybin; neuromodulation; electroconvulsive therapy; rTMS; phototherapy. Main conclusions: Bipolar affective disorder is a chronic and recurrent mood disorder characterized by alternating episodes of mania, hypomania and depression, leading to significant functional decline, increased risk of suicide and shortened life expectancy. Lithium remains the drug of first choice for the treatment and prevention of mania, while valproate and carbamazepine are effective but carry a higher risk of side effects, and atypical neuroleptics are active in both mania and depression. For treatment-resistant cases, especially refractory bipolar depression, neuromodulatory techniques (ECT, rTMS, tDCS, VNS) and the use of ketamine and psychedelics such as psilocybin show promising results. Electroconvulsive therapy is currently the best studied of these methods, rTMS and tDCS show moderate efficacy with good tolerance, ketamine provides rapid antidepressant and anti-suicidal effects despite limited long-term data, and phototherapy demonstrates beneficial effects in seasonal and non-seasonal depression with a good safety profile. Application of the study: The findings may support clinicians in improving diagnostic accuracy and optimizing treatment strategies for patients with bipolar affective disorder, particularly through a more individualized approach to the management of bipolar depression. Originality/Novelty of the study: The review integrates recent findings on emerging therapeutic perspectives in bipolar affective disorder, highlighting advances in neuromodulation, ketamine and psychedelic-assisted treatment, and their potential role in addressing treatment-resistant bipolar depression.